Population
Rat model in vivo and in vitro protein engineering models
Comparison
aDabi-Fab2 mutant Y103W vs Wild-type aDabi-Fab2 and idarucizumab
Design
Preclinical
Authors
Loading...
Longer-acting mutant supports preclinical optimization of reversal agents; leaves open human translation and safety.
Rational protein engineering of a dabigatran reversal agent candidate (aDabi-Fab2) yielded a mutant with increased affinity and longer duration of action in vivo.
Schiele et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: